WATCH THIS PROGRAM ON-DEMAND / CLICK HERE FOR COMPLIMENTARY ACCESS

Over the first half of 2019, a staggering $170B has been pledged to biopharma buyout activities, an amount that exceeds the total deal spend of the last three years combined. With the increasing complexity and frequency of biopharma M&A transactions, how do you ensure that synergy targets are met or exceeded? What are some of the key success factors, and what are some of the biggest ‘real-world’ pitfalls and watch-outs to address? In this panel we will be exploring these topics with highly experienced “roll-up-the sleeves” executives who have succeeded in M&A where others have failed. Please send your questions in advance, as this engaging talk promises to offer tangible lessons learned and takeaways. In this panel we will be exploring these topics with highly experienced “roll-up-the sleeves” executives who have succeeded in M&A where others have failed. Please send your questions in advance, as this engaging talk promises to offer tangible lessons learned and takeaways.

SPEAKERS:

Kate Hardey, Partner, McGuireWoods

Alex Zisson, Managing Director, HIG Capital

Zeid Barakat, Senior Director, Scimitar Inc.

Richard Andersen, Founder and CEO, ShareVault

MODERATOR:

Alex Kasdan, Senior Managing Director, DelMorgan & Co.

LEADING FIRMS SHARE THEIR KNOWLEDGE ON EXPERT WEBCAST: